KR101382115B1 - Health food for improving atopic dermatitis and xerosis containing ginseng fruit extracts - Google Patents
Health food for improving atopic dermatitis and xerosis containing ginseng fruit extracts Download PDFInfo
- Publication number
- KR101382115B1 KR101382115B1 KR1020070097813A KR20070097813A KR101382115B1 KR 101382115 B1 KR101382115 B1 KR 101382115B1 KR 1020070097813 A KR1020070097813 A KR 1020070097813A KR 20070097813 A KR20070097813 A KR 20070097813A KR 101382115 B1 KR101382115 B1 KR 101382115B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- atopic dermatitis
- ginseng fruit
- extract
- fruit extract
- Prior art date
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 73
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 72
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 72
- 241000208340 Araliaceae Species 0.000 title claims abstract 9
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract description 32
- 201000008937 atopic dermatitis Diseases 0.000 title abstract description 32
- 235000013402 health food Nutrition 0.000 title description 2
- 206010048222 Xerosis Diseases 0.000 title 1
- 229940068517 fruit extracts Drugs 0.000 title 1
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 53
- 239000000284 extract Substances 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 208000003251 Pruritus Diseases 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 230000007803 itching Effects 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000007602 hot air drying Methods 0.000 claims description 2
- 229940107131 ginseng root Drugs 0.000 abstract description 14
- 210000002615 epidermis Anatomy 0.000 abstract description 13
- 210000003491 skin Anatomy 0.000 abstract description 12
- 239000004615 ingredient Substances 0.000 abstract description 7
- 230000036572 transepidermal water loss Effects 0.000 abstract description 4
- 230000037365 barrier function of the epidermis Effects 0.000 abstract description 3
- 235000021028 berry Nutrition 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 description 64
- 235000002789 Panax ginseng Nutrition 0.000 description 17
- 235000005911 diet Nutrition 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 206010003645 Atopy Diseases 0.000 description 10
- 230000037213 diet Effects 0.000 description 9
- 230000000378 dietary effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229930182494 ginsenoside Natural products 0.000 description 7
- 229940089161 ginsenoside Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000006748 scratching Methods 0.000 description 5
- 230000002393 scratching effect Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside Rg2 Natural products O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000007882 dietary composition Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000036620 skin dryness Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QVSACOUKYXVIGR-UHFFFAOYSA-N 2-(3,5-dimethyl-1,2-oxazol-4-yl)ethanol Chemical compound CC1=NOC(C)=C1CCO QVSACOUKYXVIGR-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 238000009192 ultraviolet light therapy Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/90—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in food processing or handling, e.g. food conservation
Abstract
본 발명은 인삼열매 추출물을 함유하는 아토피 피부염 개선용 식품 조성물에 관한 것으로서, 보다 상세하게는 인삼의 지상부 중에서 인삼근과 차별적 성분과 조성을 갖는 인삼열매 추출물을 유효성분으로 하여 표피를 통한 수분 손실량(TEWL: trans epidermal water loss)을 감소시키고 소양증(가려움증)을 감소시킴으로써 피부 표피 장벽의 지방 층상 구조가 손상되어 있는 아토피 피부염 또는 건조증 개선용 식품 조성물에 관한 것이다. The present invention relates to a food composition for improving atopic dermatitis containing ginseng fruit extract, and more specifically, the amount of water loss through the epidermis by using ginseng fruit extract having a different ingredient and composition from ginseng root in the ground part of ginseng as an active ingredient (TEWL) : Food composition for improving atopic dermatitis or dryness in which the fatty layer structure of the skin epidermal barrier is damaged by reducing trans epidermal water loss and reducing pruritus.
인삼열매 추출물, 아토피 피부염, 수분손실량(TEWL), 소양증(가려움증) Ginseng Berry Extract, Atopic Dermatitis, Water Loss (TEWL), Pruritus (Itching)
Description
본 발명은 인삼열매 추출물을 함유하는 아토피 피부염 개선용 식품 조성물에 관한 것으로서, 보다 상세하게는 인삼의 지상부 중에서 인삼근과 차별적 성분과 조성을 갖는 인삼열매 추출물을 유효성분으로 하여 표피를 통한 수분 손실량(TEWL: trans epidermal water loss)을 감소시키고 소양증(가려움증)을 감소시킴으로써 피부 표피 장벽의 지방 층상 구조가 손상되어 있는 아토피 피부염 또는 건조증 개선용 식품 조성물에 관한 것이다. The present invention relates to a food composition for improving atopic dermatitis containing ginseng fruit extract, and more specifically, the amount of water loss through the epidermis by using ginseng fruit extract having a different ingredient and composition from ginseng root in the ground part of ginseng as an active ingredient (TEWL) : Food composition for improving atopic dermatitis or dryness in which the fatty layer structure of the skin epidermal barrier is damaged by reducing trans epidermal water loss and reducing pruritus.
인삼(Panax ginseng C.A. Meyer)은 오가피과 인삼속에 속하는 식물로서 한국, 중국 및 일본 등지에서 2,000여년 전부터 사용되어 온 생약이며, 경험적으로 질병을 예방하고 수명을 연장시킬 목적으로 사용되어 왔다. 지금까지 알려진 인삼의 효능 및 효과는 중추신경계에 대한 작용, 항발암 작용, 항암활성, 면역기능 조 절작용, 항당뇨 작용, 간기능 항진효능, 심혈관 장해개선, 항동맥경화 작용, 혈압조절 작용, 갱년기 장애 개선, 골다공증에 미치는 효과, 항스트레스, 항피로작용, 항산화 활성 및 노화억제 효능 등이 있다(최신고려인삼 '성분 및 효능편', 한국인삼연초연구원, 56-112, 1996).Ginseng (Panax ginseng C.A. Meyer) is a plant belonging to the genus Ogapi and ginseng, which has been used in Korea, China, and Japan for more than 2,000 years, and has been used to prevent disease and extend life. The effects and effects of ginseng so far known are the effects on the central nervous system, anticarcinogenic activity, anticancer activity, immune function control effect, antidiabetic effect, hepatic antifungal effect, cardiovascular disorder improvement, anti arteriosclerosis action, blood pressure control action, Improvement of menopausal disorders, effects on osteoporosis, antistress, anti-fatigue, antioxidant activity and anti-aging effects (Korea Ginseng 'Ingredients and Efficacy', Korea Ginseng and Tobacco Research Institute, 56-112, 1996).
인삼의 대표적 생리활성 성분인 진세노사이드(Ginsenoside)는 인삼의 지상 및 지하부에 고르게 분포되어 있으며, 특히 인삼 근(뿌리), 인삼엽 및 인삼열매 등 부위에 따라 진세노사이드 함량뿐만 아니라 조성도 다른 것으로 알려져 있다 (Attele AS et al, Biochem Pharmacol, 58; 1685-1693, 1999). 특히, 인삼열매는 인삼 근(뿌리)과 다른 진세노사이드 성분 함량과 성분을 바탕으로 항당뇨 효능에 있어서 인삼근 보다 우수한 결과를 나타내는 것으로 보고되었다(Dey L. et al., Phytomedicine, 10; 600-605, 2003).Ginsenoside, a representative physiologically active ingredient of ginseng, is distributed evenly in the ground and underground parts of ginseng, and in particular, ginsenoside content and composition differ depending on the parts such as ginseng root (root), ginseng leaf and ginseng fruit. (Attele AS et al, Biochem Pharmacol, 58; 1685-1693, 1999). In particular, ginseng fruit was reported to have better results than ginseng root in antidiabetic efficacy based on ginseng root (root) and other ginsenoside components and ingredients (Dey L. et al., Phytomedicine, 10; 600). -605, 2003).
한편, 인삼열매는 예로부터 인삼 보다도 귀하게 여겨지는 것으로서 종자 획득을 목적으로 선별되어 수확되어 왔다. 인삼열매는 인삼의 재배기간 중 4년생에 한해서 1회만 채종하게 되며, 3년생에서 채종하면 종자가 너무 작기 때문에 좋은 묘삼을 생산하기가 어렵고 5년생 이상에서 채종하면 종자는 충실하고 좋으나 인삼뿌리의 비대발육을 억제할 뿐만 아니라 조직이 치밀치 못하여 홍삼을 제조할 때 홍삼품질이 크게 저하될 수 있다. 또한 채종 횟수를 재배기간 중에 2회 이상 채종하면 수량 및 홍삼품질은 크게 저하된다(최신고려인삼 '재배편', 한국인삼연초연구원, 130-131, 1996).On the other hand, ginseng fruit is considered to be more precious than ginseng since ancient times, and has been selected and harvested for the purpose of obtaining seeds. Ginseng fruit is only harvested once every 4 years during the cultivation period of ginseng. It is difficult to produce good seedlings because seed is too small when grown in 3 years, and seeds are faithful and good when harvested in 5 years or more. In addition to inhibiting development, the tissue is not dense, so red ginseng quality can be greatly reduced when manufacturing red ginseng. In addition, the yield and red ginseng quality is greatly degraded when the number of cultivation is collected more than two times during the cultivation period.
한편, 피부의 가장 외층인 표피는 외부로부터 인체를 보호하는 역할을 하며 표피의 제일 상층부인 각질층이 표피 장벽(epidermal barrier)으로서 표피의 수분 증발과 손실억제, 표피의 건조화 방지, 및 세균, 곰팡이 및 바이러스 등의 피부 침범을 방지하는 인체방어 기전의 제일선 역할을 한다. 각질층은 각질 세포들 사이에 지방질들이 벽돌과 그 사이의 회반죽이 있는 형태의 층상구조를 이루고 있다. Meanwhile, the epidermis, the outermost layer of skin, serves to protect the human body from the outside. The stratum corneum, which is the uppermost layer of the epidermis, is the epidermal barrier. It serves as the first line of human defense mechanisms to prevent skin invasion such as viruses. The stratum corneum has a layered structure in which fats are located between the keratinocytes and the bricks and the plaster therebetween.
생화학적 측면에서 아토피 피부염은 피지막의 층상 구조가 손상되어 표피를 통한 수분 증발과 감염으로 인해 표피의 건조화와 과증식 및 염증의 증상을 나타내는 것으로 해석되고 있고 아토피 피부염 환자의 표피에서 세라마이드, 불포화지방산 및 자연보습 인자의 수치가 감소되어 있음이 보고되었다. 또한 건강한 피부의 경우에도 표피의 불포화 지방산 및 세라마이드 수치는 습도와 기온이 하강하는 겨울이나 노화에 의해 감소함이 알려짐으로써 표피의 건조화가 피지막의 세라마이드나 불포화 지방산 함량 변화와 역의 상관 관계가 있음을 알 수 있다. In terms of biochemistry, atopic dermatitis has been interpreted to show symptoms of dryness, hyperproliferation, and inflammation of the epidermis due to damage of the sebaceous layer of the sebaceous membrane and evaporation and infection through the epidermis. It has been reported that levels of moisturizing factors are reduced. Also, in the case of healthy skin, the level of unsaturated fatty acids and ceramides in epidermis decreases with winter and aging with decreasing humidity and temperature, indicating that drying of the epidermis is inversely correlated with changes in sebum and unsaturated fatty acid content of sebaceous membrane. Able to know.
아토피 피부염 치료제 시장은 미국, 영국, 프랑스, 독일, 이탈리아, 스페인 및 일본 시장을 합쳐 1999년에 5억 6천만 달러를 넘어섰고, 2009년에는 12억 달러에 이를 것으로 예측되고 있다. 현재는 외국 시장 역시 국소용 코르티코스테로이드 제제가 주도하고 있으며, 그 외에 비타민 D 외용제, 안스랄린(anthralin), 타르 제제, 경구용 항히스타민제 및 2세대 레티노이드 등이 사용되고 있다.The Atopic Dermatitis Therapeutics Market surpassed US $ 560 million in 1999, combined with US, UK, France, Germany, Italy, Spain and Japan, and is expected to reach US $ 1.2 billion in 2009. Currently, the foreign market is also led by topical corticosteroid preparations, and vitamin D external preparations, anthralin, tar preparations, oral antihistamines, and second-generation retinoids are used.
면역 억제를 통한 치료제로는 사일클로 스포린과 메토트렉세이트 (methotrexate) 등이 사용되어 왔으나 매출액은 크지 않다. 그러나 향후의 시장 증대는 기존의 국소용 코르티코스테로이드를 대체할 것으로 기대되는 타클로리무스(tacrolimus, 프로토픽)나 피메크로리무스(pimecrolimus, 엘리델) 등의 면역억제 신약에 의해 주도될 것으로 예측되고 있다. 국내 2002년 아토피 제품(의약품+화장품)의 잠재시장 규모는 1000억원대로 예상하고 있으며 그 중 스테로이드 제제가 280억원으로 가장 크다.Cyclosporine and methotrexate have been used as treatments for immune suppression, but sales are not high. However, future market growth is expected to be driven by immunosuppressive drugs such as tacrolimus (protocol) and pimecrolimus (Elidel), which are expected to replace conventional topical corticosteroids. In 2002, the potential market for atopy products (pharmaceuticals + cosmetics) is estimated at W100bn, of which steroid drugs are the largest, at W28bn.
우리나라의 경우 피부 건조화가 일어나는 피부 질환 중 아토피 피부염은 전체 인구의 약 10~20%에서 발병하는 대표적인 피부질환으로서 우리나라 피부과 외래 환자의 5% 이상을 차지하고 있다. 이에 아토피성 피부질환 시장은 매년 50% 이상 고속 성장하고 있고 시장 잠재력이 크다는 점에서 벤처기업, 제약기업 및 화장품업소 등에서 관심을 집중하고 있다. 또한 화장품과 의약품 등은 할인점이나 약국 등의 유통시장이 한정되어 있으나, 약국 의료기관 화장품 전문업소 등 유통채널이 다양하다는 점도 특징 중의 하나이다. 아토피성 피부 질환 시장 중 화장품 시장은 98년 이후 지속적으로 성장하여 2001년에 150억, 2002년에 250억원 2003년 400억원대로 성장하였다. In Korea, atopic dermatitis is one of the skin diseases that cause skin dryness, and it is a representative skin disease that occurs in about 10-20% of the total population. The atopic dermatitis market is growing at a rate of over 50% every year, and the market is attracting attention from venture companies, pharmaceutical companies, and cosmetics companies. In addition, the distribution market of cosmetics and pharmaceuticals, such as discount stores and pharmacies is limited, but one of the characteristics is that the distribution channels such as pharmacy medical institutions and cosmetics specialists are diverse. The cosmetics market in the atopic dermatitis market continued to grow since 1998, to 15 billion won in 2001 and 25 billion won in 2002 and 40 billion won in 2003.
< 2003년도 아토피 환자수 및 처방수 조사 ><2003 Atopic Patient Count and Prescription Count Survey>
<성별/나이에 따른 아토피 환자><Atopic Patients by Sex / Age>
2003/22002/9 ~
2003/2
2003/92002/9 ~
2003/9
(남자)(man)
2003/22002/9 ~
2003/2
2003/92002/9 ~
2003/9
(여자)(Woman)
2003/22002/9 ~
2003/2
2003/92002/9 ~
2003/9
(합계)(Sum)
아토피 피부염 환자 표피에서의 세라마이드 불포화 지방산 및 자연보습인자의 수치 감소 보고와 더불어 피부의 건조화 방지 및 부드럽고 촉촉한 느낌은 피부의 건강 차원에서 영양과 밀접한 관련이 있다는 일반인들의 인식변화에 따라 특정 영양소 성분, 특히 불포화 지방산의 피지막 유지 및 보습 기능에 대한 연구가 미국 및 유럽을 중심으로 진행되고 있으나 우리나라에서는 피부 보습 증진을 위한 건강 기능 식품 소재 개발 및 제품화에 대한 연구가 미흡한 실정이다.In addition to reporting reduced levels of ceramide-unsaturated fatty acids and natural moisturizing factors in the epidermis of atopic dermatitis patients, specific nutrients, especially in response to changes in the public's perception that skin's dryness prevention and soft, moist feeling are closely related to nutrition in terms of skin health Although studies on sebum membrane maintenance and moisturizing function of unsaturated fatty acids are conducted in the US and Europe, studies on the development and production of health functional food materials for enhancing skin moisturization are insufficient in Korea.
아토피 피부염의 현행치료법으로 국소용 스테로이드제제, 항히스타민제 및 자외선 요법이 이용되고 있으나 이와 같은 치료법들은 여러 부작용을 수반하고 있고 근본적인 치유를 기대하기 어려우며 염증의 악화 방지와 재발되기까지의 완화기간을 장기화하는데 의의를 두고 있는 것뿐이어서, 부작용을 수반하지 않고 장기간 사용할 수 있는 치료제의 개발이 시급한 실정이다. 또한 최근에는 세라마이드를 함유하여 보습력이 강화된 로션들이 선호되고 있으나 이 또한 빈번한 도포를 필요로 하며 일시적인 건조화 증상 완화의 효과를 나타낼 뿐이어서 부작용을 수반하지 않고 장기간 사용할 수 있는 치료제의 개발이 시급한 실정이다.Topical steroids, antihistamines, and ultraviolet light therapy are used as current treatments for atopic dermatitis, but these treatments have several side effects, are difficult to expect fundamental healing, and prevent the deterioration of inflammation and prolong the remission period until recurrence. Since it is only meaningful, it is urgent to develop a therapeutic agent that can be used for a long time without any side effects. In addition, moisturizing lotions with ceramides have recently been preferred, but this also requires frequent application and shows temporary relief of temporary drying symptoms. Therefore, it is urgent to develop a therapeutic agent that can be used for a long time without side effects. .
이에, 본 발명자들은 인삼의 지하부인 인삼근 외에도 지상부인 인삼열매를 이용하여 아토피 피부염을 개선하는 천연 소재를 찾고자 연구를 하던 중 인삼열매 추출물이 일반적인 인삼근 및 홍삼과는 다른 성분과 조성에 의한 아토피 피부염 개선 및 건조증 개선 효능이 있음을 발견하고, 본 발명을 완성하게 되었다.Thus, the present inventors while researching to find a natural material that improves atopic dermatitis by using ginseng fruit, which is the ground part of ginseng, in addition to the ginseng root which is the underground part of ginseng, the ginseng fruit extract is different from general ginseng root and red ginseng by atopy It has been found that there is an improvement in dermatitis and dryness, and the present invention has been completed.
따라서, 본 발명의 목적은 인삼열매 추출물을 유효성분으로 함유하는 아토피 피부염 개선용 식품 조성물을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a food composition for improving atopic dermatitis containing ginseng fruit extract as an active ingredient.
본 발명의 다른 목적은 인삼열매 추출물을 유효성분으로 함유하는 피부 가려움 증상 개선용 식품 조성물을 제공하는 것이다. Another object of the present invention to provide a food composition for improving the skin itching symptoms containing ginseng fruit extract as an active ingredient.
상기한 목적을 달성하기 위하여, 본 발명은 인삼열매 추출물을 유효성분으로 함유하는 아토피 피부염 개선용 식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a food composition for improving atopic dermatitis containing ginseng fruit extract as an active ingredient.
또한 본 발명은 인삼열매 추출물을 유효성분으로 함유하는 피부 가려움 증상 개선용 식품 조성물을 제공한다. In another aspect, the present invention provides a food composition for improving skin itching symptoms containing ginseng fruit extract as an active ingredient.
본 발명에서는 인삼열매 추출물이 건강식품의 형태에 따라 조성물 총 중량에 대하여 0.01~100 중량% 로 혼합될 수 있다. In the present invention, ginseng fruit extract may be mixed in an amount of 0.01 to 100% by weight based on the total weight of the composition according to the form of health food.
본 발명에 의한 인삼열매 추출물을 함유한 아토피 피부염 개선용 식품 조성 물은 표피의 수분손실(TEWL: tans epidermal water loss)을 억제하였으며 동시에 소양증(가려움증)을 개선시킴으로써 우수한 아토피 피부염의 개선 효능을 나타내었다. Food composition for improving atopic dermatitis containing ginseng fruit extract according to the present invention inhibited the epidermal water loss (TEWL) of the epidermis and at the same time showed an excellent effect of improving atopic dermatitis by improving pruritus (itch). .
본 발명에서 상기 인삼 열매 추출물은 인삼 열매의 종자를 분리하여 제거한 과육과 과피를 일광건조 또는 열풍건조하여 수득한 인삼열매 건조원료에 물 또는 에탄올을 가하여 추출함으로써 제조되는 것을 사용한다.In the present invention, the ginseng fruit extract is prepared by adding water or ethanol to the ginseng fruit dry raw material obtained by sun drying or hot air drying to remove the flesh and skin peeled by separating the seeds of the ginseng fruit.
이하에서는 실시예를 통하여 본 발명을 보다 구체적으로 설명한다. 그러나, 이들 실시예는 본 발명을 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명한 것이다.Hereinafter, the present invention will be described in more detail with reference to examples. It will be apparent, however, to those skilled in the art that these embodiments are for describing the present invention and that the scope of the present invention is not limited to these embodiments.
[실시예 1] 인삼 열매 추출물 제조[Example 1] Preparation of ginseng fruit extract
1) 인삼 열매 전처리: 생(生)인삼 열매를 수확하여 종자를 분리하고 제거한 후 인삼 열매의 과육과 과피를 일광건조 또는 열풍건조를 통하여 인삼 열매 건조원료를 제조하였다.1) Ginseng fruit pretreatment: The raw ginseng fruit was harvested and the seeds were separated and removed. Then, the ginseng fruit and the skin of the ginseng fruit were dried with sunlight or hot air to prepare ginseng fruit raw material.
2) 인삼 열매 추출물 제조: 인삼 열매 건조물 1kg에 에탄올 3L를 가하여 환류 추출한 다음 여과한 후 40~45℃에서 감압농축하여 인삼 열매 추출물 300g을 얻 었다.2) Preparation of ginseng fruit extract: 1 g of dried ginseng fruit extract was added to 3 L of ethanol to extract reflux, and then filtered and concentrated under reduced pressure at 40 ~ 45 ℃ to obtain 300 g of ginseng fruit extract.
[비교예 1] 인삼근 추출물 제조[Comparative Example 1] Production of ginseng muscle root extract
상기 실시예 1에서 인삼 열매 대신에 인삼근(뿌리)을 사용한 것을 제외하고 실시예 1과 동일한 방법으로 제조하였다.Example 1 was prepared in the same manner as in Example 1, except that ginseng root (root) was used instead of ginseng fruit.
[시험예 1] 인삼 열매 추출물의 성분비교[Test Example 1] Comparison of components of ginseng fruit extract
<인삼 열매와 인삼근의 진세노사이드(인삼사포닌) 성분분석><Analysis of Ginsenoside (Ginseng Saponin) Components of Ginseng Fruit and Ginseng Root>
실시예 1 및 비교예 1에서 각각 인삼 열매와 인삼근 추출물을 제조한 다음 이들 추출물에 에테르(ether)를 처리하여 지용성 성분을 제거한 후 부탄올(BuOH)로 조사포닌을 추출, 농축하여 HPLC를 통한 진세노사이드 성분분석을 실시하였으며, 그 결과를 도 1 및 표 5에 나타내었다.In Example 1 and Comparative Example 1, respectively, ginseng fruit and ginseng root extract were prepared, and then, the extracts were treated with ether to remove fat-soluble components, followed by extracting and concentrating ginsponin with butanol (BuOH). Cenoside component analysis was carried out, and the results are shown in FIGS. 1 and 5.
(건조중량)Crude saponin content
(Dry weight)
33.42%
33.42%
16.70%
16.70%
실시예 1에서 제조한 인삼 열매 추출물은 조사포닌 함량에 있어서 비교예 1에서 제조한 인삼근 추출물의 약 2배 함량을 가지고 있었으며, 진세노사이드를 PD(Protopanaxadiol)계-"진세노사이드 Rb1, Rb2, Rc 및 Rd" 및 PT(Protopanaxatriol)계-"진세노사이드 Re, Rg1 및 Rg2"의 비율로 구분하였을 때 각각 0.73과 3.23으로 그 조성에 있어서 인삼 열매와 인삼근은 뚜렷한 차이 및 특징을 나타내었다.The ginseng fruit extract prepared in Example 1 had about twice the crude ginsenoside content of the ginseng root extract prepared in Comparative Example 1, and the ginsenoside was divided into PD (protopanaxadiol) -ginsenoside Rb1, Rb2 , Rc and Rd "and PT (Protopanaxatriol) system -" Ginsenoside Re, Rg1 and Rg2 ", the ginseng fruit and ginseng root showed distinct differences and characteristics in the composition of 0.73 and 3.23 respectively .
<인삼 열매 추출물의 미네랄 성분분석><Mineral composition analysis of ginseng fruit extract>
실시예 1에서 제조한 인삼 열매 추출물이 인삼과는 다른 '과실'로서의 특징을 가짐을 구분하기 위하여 비타민을 비롯한 미네랄 성분 분석을 실시하였으며, 그 결과를 하기 표 6에 나타내었다.In order to distinguish the ginseng fruit extract prepared in Example 1 has the characteristics of 'fruit' different from ginseng, mineral components including vitamins were analyzed, and the results are shown in Table 6 below.
이상과 같이 본 발명에서 사용하는 인삼 열매의 성분적 특성은 인삼근 보다 많은 인삼사포닌을 함유함과 동시에 사포닌 조성의 성질이 정반대이고, 또한 인삼근과 달리 열매로서 비타민과 미네랄 16 종의 함량이 풍부함을 확인할 수 있었으며, 이를 바탕으로 피부효능에 대한 하기 실험들을 진행하였다.As described above, the constituent characteristics of the ginseng fruit used in the present invention is that the ginseng saponin is contained in a larger amount than that of the ginseng root, and the saponin composition properties are opposite to each other. Also, unlike the ginseng root, the content of 16 kinds of vitamins and minerals is rich , And based on this, the following experiments on skin efficacy were conducted.
[비교예 2] 홍삼추출물 제조Comparative Example 2 Preparation of Red Ginseng Extract
홍삼분말 1kg에 에탄올 6L를 가하고, 상온/환류 추출을 3회 실시한 후 추출원액은 통상의 방법으로 여과과정을 거친 다음 감압농축기를 이용하여 농축시켜 250g의 홍삼추출물을 얻었다.6 kg of ethanol was added to 1 kg of red ginseng powder, and the mixture was extracted three times at room temperature and refluxed. The extract was filtered using a conventional method and concentrated using a reduced pressure concentrator to obtain 250 g of red ginseng extract.
[시험예 2] 생체 내(in vivo)에서의 아토피 피부염 및 건조증 개선 효과[Test Example 2] Atopic dermatitis and dryness improvement effect in vivo
<실험 동물>Experimental Animal
아토피 마우스(NC/Nga Tnd mice)와 정상 대조군 마우스를 온도 22±1℃, 습도 60±5%로 유지시키고 12시간 간격으로 명암을 바꿔주면서 적응시켰다. Atopy mice (NC / Nga Tnd mice) and normal control mice were maintained at a temperature of 22 ± 1 ° C. and a humidity of 60 ± 5% and adapted to varying contrast at 12 hour intervals.
<식이구성>Dietary Composition
실험 식이로 사육하기 전 1주 동안 고형배합 사료로 적응시켰고 체중에 따라 난괴법으로 나누어 실험 식이를 NC/Nga Tnd 마우스에게 10주간 공급하였다. 각 실험군의 식이 조성은 하기 표 7에 기재하였으며, 비교예 2의 홍삼추출물과 실시예 1의 인삼열매 추출물은 전체 식이 무게의 5%에 상응하는 원료를 각각 식이에 혼합하여 공급하였다. 따라서, 본 실험군은 정상대조군, 아토피 피부염군 및 홍삼추출물함유 식이 아토피 피부염군(비교예 2 함유군) 및 인삼열매 추출물함유 식이 아토피 피부염군(실시예 1 함유군)으로 나누어 실험하였다. Adapted to a solid blended feed for 1 week before breeding into the experimental diet and divided into egg mass according to body weight, the experimental diet was fed to NC / Nga Tnd mice for 10 weeks. The dietary composition of each experimental group is shown in Table 7 below, and the red ginseng extract of Comparative Example 2 and the ginseng fruit extract of Example 1 were supplied with a mixture of raw materials corresponding to 5% of the total diet weight. Therefore, the experimental group was divided into the normal control group, atopic dermatitis group and red ginseng extract-containing diet atopic dermatitis group (Comparative Example 2 containing group) and ginseng fruit extract containing dietary atopic dermatitis group (Example 1 containing group).
(n=10)Normal control group
(n = 10)
(n=10)Atopic dermatitis
(n = 10)
식이 아토피
유발군 (n=10)Contains red ginseng extract
Dietary Atopy
Trigger group (n = 10)
식이 아토피
유발군 (n=10)Contains ginseng fruit extract
Dietary Atopy
Trigger group (n = 10)
- 정상대조군: 정상식이 공급받는 NC/Nga Tnd 마우스-Normal control group : NC / Nga Tnd mouse fed normal diet
- 아토피 피부염군: 아토피 유발 실험군 NC/Nga Tnd 마우스-Atopic Dermatitis Group: NC / Nga Tnd Mouse
- 홍삼추출물 함유 식이 아토피 유발군: 아토피 유발 실험군 NC/Nga Tnd 마우스 + 홍삼추출물Dietary atopic induction group containing red ginseng extract: NC / Nga Tnd mouse + red ginseng extract
- 인삼열매 추출물 함유 식이 아토피 유발군: 아토피 유발 실험군 NC/Nga Tnd 마우스 + 인삼열매 추출물-Dietary Atopic Dermal Group Containing Ginseng Fruit Extract: NC / Nga Tnd Mouse + Ginseng Fruit Extract
<식이 효율 측정>Dietary efficiency measurement
식이효율을 측정하기 위하여 1주일에 두 번씩 쥐 각각의 무게, 남은 식이량 및 식이 공급량을 측정하였다. To determine dietary efficiency, the weight of each rat, the amount of food remaining and the amount of food supplied were measured twice a week.
<표피의 수분 손실량(Trans Epidermal Water Loss: TEWL) 측정><Measurement of Trans Epidermal Water Loss (TEWL)>
실시예 1의 인삼열매 추출물과 비교예 2의 홍삼추출물에 의해 표피의 수분손실(TEWL: tans epidermal water loss)이 얼마나 영향을 미치는지 알아보았다.It was examined how the epidermal water loss (TEWL) of epidermis was affected by the ginseng fruit extract of Example 1 and the red ginseng extract of Comparative Example 2.
실험 동물의 도살 전 등 부위를 면도하고 30분간 항온 항습이 유지되는 공간에서 30분간 방치한 후 비중계(Hydrometer)의 탐침을 등 부위 피부 표면에 밀착 접촉하여 가볍게 눌러서 나타나는 수치를 기록하였으며, 그 결과를 도 2에 도시하였다. After shaving the back part of the experimental animal and leaving it for 30 minutes in a space where constant temperature and humidity were maintained, the numerical value that was lightly pressed by touching the hydrometer's probe in close contact with the back skin surface was recorded. 2 is shown.
각질층의 수분함량은 표피에서 생성 분비되는 지질 혼합체인 피지막과 각질층내에 존재하는 수용성 성분인 자연보습인자(NMF: Natural Moisturizing Factor)에 의해 결정된다. The moisture content of the stratum corneum is determined by the sebaceous membrane, the lipid mixture produced and secreted by the epidermis, and the natural moisturizing factor (NMF), a water-soluble component present in the stratum corneum.
기후, 계절 및 자외선 등의 환경적 요인, 유전, 노화, 호르몬, 면역, 스트레스 및 영양 상태 등의 내인성 인자들의 변화에 의해 피지막과 자연보습인자의 생성이 감소하면 표피의 수분손실량(TEWL: tans epidermal water loss)이 증가하여 피부가 건조해지며 표면이 메마르고 꺼칠꺼칠하여 각질이 일어난다.If the production of sebaceous membranes and natural moisturizing factors decreases due to changes in endogenous factors such as climate, seasons, environmental factors such as UV, genetics, aging, hormones, immunity, stress, and nutritional status, the epidermal moisture loss (TEWL) Increased water loss causes skin to dry, and the surface becomes dry and dull, resulting in dead skin cells.
도 2의 결과에서, 10주간의 식이 공급 후 각 군의 경표피 손실량을 측정한 결과, 아토피 피부염 대조군인 아토피 피부염군에서 가장 높았고, 정상군 대조군에서 가장 낮았으며, 비교예 2의 홍삼추출물 함유 식이 아토피 피부염군(비교예 2 함유군) 보다 실시예 1의 인삼열매 추출물 식이 아토피 피부염군(실시예 1 함유군)이 정상대조군 수준으로 표피 수분손실량을 억제하여 비교예 2의 홍삼추출물보다 실시예 1의 인삼열매 추출물이 경표피 수분 손실량(TEWL) 억제 효과가 뛰어난 것을 확인할 수 있었다.In the results of Figure 2, after measuring the epidermal loss of each group after a 10-week diet, the highest in the atopic dermatitis group, atopic dermatitis control group, the lowest in the normal group control group, the diet containing red ginseng extract of Comparative Example 2 The ginseng fruit extract diet of Example 1 than the atopic dermatitis group (Comparative Example 2 containing group) suppresses the epidermal moisture loss to the normal control group level compared to the red ginseng extract of Comparative Example 2 Ginseng fruit extract was found to be excellent in inhibiting the epidermal moisture loss (TEWL).
<아토피 피부염 일반적 임상 증상 측정: 가려움에 대한 행동학적 분석>Measurement of general clinical symptoms of atopic dermatitis: behavioral analysis of itching
각 군에서 5마리를 1주 단위로 20분간 자동 비디오 카메라(automatic video camera)를 이용하여 촬영하고 얼굴, 귀 및 목을 비롯한 전신을 긁는 횟수를 측정하여 기록하였다. 아토피 유발 NC/Nga mice의 소양증에 대한 유형은 개체 간에 다양하므로 긁는 정도(scratching intensity)와 시간(scratching duration)에 상관없이 단위 시간당(20분) 각 개체의 긁는 횟수만을 측정하여 실험군간의 유의성을 통계학적으로 분석하였으며, 그 결과를 도 3에 나타내었다. Five groups in each group were photographed using an automatic video camera for 20 minutes each week, and the number of scratches of the whole body including the face, ear and neck was measured and recorded. Since the types of pruritus of atopy-induced NC / Nga mice vary among individuals, the significance of the experimental groups was measured by measuring only the number of scratches of each subject per unit time (20 minutes), regardless of the scratching intensity and the scratching duration. Analytically, the results are shown in FIG. 3.
도 3의 결과에서, 본 발명에 의한 실시예 1의 인삼열매 추출물 함유 식이 아토피 피부염군(실시예 1 함유군)에서는 소양증(가려움증) 증가 등 아토피 피부염의 일반적인 증상을 수반하는 아토피 피부염 동물모델인 NC/Nga 마우스에서 소양증(scratching number)이 비교예 2의 홍삼추출물 함유 식이 아토피 피부염군(비교예 2 함유군)보다 현저히 감소하였다. 이 결과는 본 발명에 의한 실시예 1의 인삼열매 추출물이 소양증(가려움증)을 개선시킴을 보여주는 것이다.In the results of Figure 3, NC in the atopic dermatitis animal model with general symptoms of atopic dermatitis, including pruritus (itch) increase in the dietary atopic dermatitis group (Example 1 containing group) of the ginseng fruit extract of Example 1 according to the present invention Scratching number in / Nga mice was significantly reduced compared to the atopic dermatitis group (Comparative Example 2 containing group) containing red ginseng extract of Comparative Example 2. This result shows that the ginseng fruit extract of Example 1 according to the present invention improves pruritus (itch).
도 1은 실시예 1의 인삼 열매 추출물과 비교예 1의 인삼 추출물의 진세노사이드 성분을 분석한 그래프이다.FIG. 1 is a graph showing ginsenoside components of the ginseng fruit extract of Example 1 and the ginseng extract of Comparative Example 1. FIG.
도 2는 시험물질에 대한 표피를 통한 수분손실량(Trans epidermal water loss)을 보여주는 그래프이다.Figure 2 is a graph showing the amount of water (Trans epidermal water loss) through the epidermis for the test substance.
도 3은 시험물질의 식이 공급이 소양증(scratching number)에 미치는 영향을 알아보기 위하여 긁는 횟수(Scratching Number; count/20min)를 측정한 그래프이다(Values are mean ±SD(n=10), means with different letters differ P < 0.05).3 is a graph measuring the scratching number (count / 20min) to determine the effect of the dietary supply of the test substance on the scratching number (Values are mean ± SD (n = 10), means with different letters differ P <0.05).
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070097813A KR101382115B1 (en) | 2007-09-28 | 2007-09-28 | Health food for improving atopic dermatitis and xerosis containing ginseng fruit extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070097813A KR101382115B1 (en) | 2007-09-28 | 2007-09-28 | Health food for improving atopic dermatitis and xerosis containing ginseng fruit extracts |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090032501A KR20090032501A (en) | 2009-04-01 |
KR101382115B1 true KR101382115B1 (en) | 2014-04-08 |
Family
ID=40759308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070097813A KR101382115B1 (en) | 2007-09-28 | 2007-09-28 | Health food for improving atopic dermatitis and xerosis containing ginseng fruit extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101382115B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160019190A (en) | 2014-08-11 | 2016-02-19 | 재단법인 금산국제인삼약초연구소 | Composition comprising fermented ginseng or red ginseng extract containing increased ginsenoside Rd for improving atopic dematitis |
KR20180018625A (en) | 2018-02-07 | 2018-02-21 | 재단법인 경기도경제과학진흥원 | Cosmetic Composition for Improving Atopic Dermatitis Comprising Extract of Tagetes Minuta |
KR20190082495A (en) | 2018-01-02 | 2019-07-10 | 이병성 | Cream manufacturing method for the improvement of atopic skin |
KR20220049471A (en) | 2020-10-14 | 2022-04-21 | 동국대학교 경주캠퍼스 산학협력단 | Composition for preventing, improving or treating atopic dermatitis |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102144318B1 (en) * | 2017-01-26 | 2020-08-13 | (주)아모레퍼시픽 | Composition for enhancing immunity comprising Ginseng berry polysaccharide |
KR102026780B1 (en) | 2017-11-03 | 2019-10-01 | 대한민국 | Black ginseng extract for skin whitening and manufacturing method thereof |
KR102026783B1 (en) | 2017-11-03 | 2019-09-30 | 대한민국 | Fermented Extract of Ginseng Leaf for Skin Whitening and manufacturing method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1053532A (en) * | 1996-08-08 | 1998-02-24 | Ichimaru Pharcos Co Ltd | Antiallergic drug containing plant extract |
KR20050045980A (en) * | 2005-04-29 | 2005-05-17 | 김동현 | Health supplement food containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease |
JP2005304369A (en) | 2004-04-21 | 2005-11-04 | Rasheru Seiyaku Kk | Health supplement containing panax ginseng, ganoderma lucidum or extract thereof |
KR20080094499A (en) * | 2007-04-20 | 2008-10-23 | (주)아모레퍼시픽 | Health food for improving skin beauty containing ginseng fruit extracts |
-
2007
- 2007-09-28 KR KR1020070097813A patent/KR101382115B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1053532A (en) * | 1996-08-08 | 1998-02-24 | Ichimaru Pharcos Co Ltd | Antiallergic drug containing plant extract |
JP2005304369A (en) | 2004-04-21 | 2005-11-04 | Rasheru Seiyaku Kk | Health supplement containing panax ginseng, ganoderma lucidum or extract thereof |
KR20050045980A (en) * | 2005-04-29 | 2005-05-17 | 김동현 | Health supplement food containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease |
KR20080094499A (en) * | 2007-04-20 | 2008-10-23 | (주)아모레퍼시픽 | Health food for improving skin beauty containing ginseng fruit extracts |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160019190A (en) | 2014-08-11 | 2016-02-19 | 재단법인 금산국제인삼약초연구소 | Composition comprising fermented ginseng or red ginseng extract containing increased ginsenoside Rd for improving atopic dematitis |
KR20190082495A (en) | 2018-01-02 | 2019-07-10 | 이병성 | Cream manufacturing method for the improvement of atopic skin |
KR20180018625A (en) | 2018-02-07 | 2018-02-21 | 재단법인 경기도경제과학진흥원 | Cosmetic Composition for Improving Atopic Dermatitis Comprising Extract of Tagetes Minuta |
KR20220049471A (en) | 2020-10-14 | 2022-04-21 | 동국대학교 경주캠퍼스 산학협력단 | Composition for preventing, improving or treating atopic dermatitis |
Also Published As
Publication number | Publication date |
---|---|
KR20090032501A (en) | 2009-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107854367B (en) | Essence for repairing sensitive skin | |
KR101382115B1 (en) | Health food for improving atopic dermatitis and xerosis containing ginseng fruit extracts | |
JP6873517B2 (en) | Health-maintaining product composition applicable to adult women, the elderly and people in sub-health conditions | |
US6395311B2 (en) | Multicomponent biological vehicle | |
KR101208012B1 (en) | Cosmetic composition containing snail mucus fed with red ginseng and producing method thereof | |
Kamboj et al. | Evaluation of antidiabetic activity of hydroalcoholic extract of cestrum nocturnum leaves in streptozotocin-induced diabetic rats | |
KR101098400B1 (en) | A method for mucus of acusta despecta sieboldiana feed red ginseng and cosmetic composition containing thereof | |
KR20150005430A (en) | Composition for relieving premenstrual syndrome and menstrual pain | |
KR101760418B1 (en) | Composition comprising extracts of sophora flavescens, glycyrrhiza uralensis fischer and dictamnus dasycarpus turcz for preventing and treating atopic dermatitis and method of preparering the same | |
CN115317429A (en) | Composition containing recombinant collagen and having repairing and relieving effects, eye cream containing composition, preparation method and application | |
CN108704021A (en) | The composition and preparation method impaired for skin allergy and skin barrier | |
KR20110128384A (en) | The composition material and the manufacturing process for skin-wrinkle, moisture and skin-lightening uses by midam-kyungokko | |
CN114794478A (en) | Composition capable of reducing blood pressure, blood fat and blood sugar and application thereof | |
KR101349246B1 (en) | Health food for improving skin beauty containing ginseng fruit extracts | |
KR20110095765A (en) | Anti-allergic composition containing scrophularia buergeriana extract | |
KR20050079913A (en) | Hovenia dulcis extract for treatment of obesity | |
KR100975426B1 (en) | Composition comprising the crude extract for preventing and treating allergic skin diseases | |
KR20210068936A (en) | Composition for improved atopy skin and skin moisturizing comprising natural extract | |
KR101231446B1 (en) | Pharmaceutical Composition and heath care food comprising the extract of complex herb an active ingredient for preventing and treating allergic or non-allergic skin disease | |
Nurhayati et al. | Therapy of cinnamon decoction using honey in reducing gout. | |
KR102450143B1 (en) | Composition for improving, preventing or treating skin disease comprising Thymus plant extract | |
CN109248192B (en) | Method for reducing body weight | |
Jafri et al. | Effect of Momordica charantia (karela) in alloxan induced diabetic rats | |
KR101784370B1 (en) | Composition for prevention or treatment of atopic dermatitis comprising aronia and moringa extract | |
KR101986008B1 (en) | Pharmaceutical composition for preventing or treating atopic dermatitis comprising extract of resveratrol-enriched rice or resveratrol enriched rice callus as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170329 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180329 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190325 Year of fee payment: 6 |